COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A6NU
|
|||
| Drug Name |
Haloperidol
|
|||
| Synonyms |
Haldol; Aloperidin; Serenace; Aloperidol; Eukystol; Brotopon; Einalon S; Ulcolind; Serenase; Uliolind; Serenelfi; Aloperidolo; Vesalium; Halopoidol; Galoperidol; Halojust; Pernox; Mixidol; Halopal; Linton; Sernel; Sernas; Dozic; Aldo; Lealgin compositum; Keselan; Peluces; Bioperidolo; Haldol Solutab; McN-JR-1625; Haloperidolum; Aloperidon; Fortunan; Aloperidolo [DCIT]; Aloperidolo [Italian]; Haloperidolum [INN-Latin]
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) | Investigative | [1] | |
| Other Indication | Schizophrenia | Approved | [2] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H23ClFNO2
|
|||
| Canonical SMILES |
C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
|
|||
| InChI |
1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
|
|||
| InChIKey |
LNEPOXFFQSENCJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 52-86-8
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:5613
|
|||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN opioid receptor sigma 1 (OPRS1) | Target Info | Modulator | [3] |
| Haloperidol binds to opioid receptor sigma 1, which participates in ER stress response and thus leads to inhibition of its interaction with SARS-CoV-2 Nsp6 protein. | ||||
| HUMAN sigma intracellular receptor 2 (TMEM97) | Target Info | Modulator | [3] | |
| Haloperidol binds to opioid receptor sigma 1, which participates in ER stress response and thus leads to inhibition of its interaction with SARS-CoV-2 Nsp6 protein. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Sigma-1Rs are upregulated via PERK/eIF2/ATF4 pathway and execute protective function in ER stress. Biochem Biophys Res Commun. 2011 Nov 25;415(3):519-25. | |||
| 2 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 076035. | |||
| 3 | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.